MedPath

Mecamylamine

Generic Name
Mecamylamine
Brand Names
Inversine, Vecamyl
Drug Type
Small Molecule
Chemical Formula
C11H21N
CAS Number
60-40-2
Background

A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.

Indication

For the treatment of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension

Associated Conditions
Severe Hypertension, Moderate Hypertension, Uncomplicated Malignant hypertension
Clinical Trials
Related News

Safety and Efficacy of ATG003 in Patients With Wet Age-Related Macular Degeneration (AMD)

Phase 2
Terminated
Conditions
Macular Degeneration
Interventions
Drug: Placebo
First Posted Date
2006-12-21
Last Posted Date
2010-11-23
Lead Sponsor
CoMentis
Target Recruit Count
343
Registration Number
NCT00414206
Locations
🇲🇽

Hospital San José Tec de Monterrey, Monterrey, Mexico

🇵🇱

Oddział Okulistyczny Okręgowy Szpital Kolejowy, Katowice, Poland

🇵🇱

Oddział Okulistyki, Samodzielny Publiczny Szpital Kliniczny Nr 1 Przemienienia Pańskiego AM w Poznaniu, Poznań, Poland

and more 38 locations

Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients

Phase 2
Completed
Conditions
Alcoholism
Interventions
Drug: Placebo
First Posted Date
2006-06-21
Last Posted Date
2019-06-04
Lead Sponsor
Yale University
Target Recruit Count
136
Registration Number
NCT00342563
Locations
🇺🇸

VA Connecticut Healthcare System, West Haven, Connecticut, United States

Nicotinic Receptor Augmentation of SSRI Antidepressants

Phase 2
Completed
Conditions
Depressive Disorder
First Posted Date
2006-04-27
Last Posted Date
2007-04-19
Lead Sponsor
Yale University
Target Recruit Count
60
Registration Number
NCT00319319
Locations
🇺🇸

Connecticut Mental Health Center, New Haven, Connecticut, United States

Treatment of Orthostatic Intolerance

Phase 1
Active, not recruiting
Conditions
Tachycardia
Chronic Orthostatic Intolerance
Interventions
Dietary Supplement: Melatonin
Other: NO Drug
Radiation: Placebo
Device: Breathing Device
Other: Drinking Water
Procedure: IV Saline
Device: Abdominal binder
First Posted Date
2005-12-06
Last Posted Date
2024-10-02
Lead Sponsor
Satish R. Raj
Target Recruit Count
150
Registration Number
NCT00262470
Locations
🇺🇸

Vanderbilt University Autonomic Dysfunction Center, Nashville, Tennessee, United States

Combinations of Pharmacologic Smoking Cessation Treatments

Phase 1
Completed
Conditions
Smoking
First Posted Date
2001-07-05
Last Posted Date
2009-01-21
Lead Sponsor
US Department of Veterans Affairs
Registration Number
NCT00018187
Locations
🇺🇸

VA Greater Los Angeles Healthcare System, Los Angeles, California, United States

Treatment to Quit Smoking

Phase 2
Completed
Conditions
Smoking
First Posted Date
2001-07-05
Last Posted Date
2009-01-21
Lead Sponsor
US Department of Veterans Affairs
Registration Number
NCT00018161
Locations
🇺🇸

Veterans Affairs Medical Center, Durham, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy